Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Liver
Descriptor: Met expression


Reference Number: 72
Kiss, A., Wang, N. J., Xie, J. P. & Thorgeirsson, S. S. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 3, 1059-66 (1997).
PubMed link      E-mail link

Reference Number: 73
Ljubimova, J. Y., Petrovic, L. M., Wilson, S. E., Geller, S. A. & Demetriou, A. A. Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 45, 79-87 (1997).
PubMed link      E-mail link

Reference Number: 74
Schoedel, K. E., Tyner, V. Z., Kim, T. H., Michalopoulos, G. K. & Mars, W. M. HGF, MET, and Matrix-Related Proteases in Hepatocellular Carcinoma, Fibrolamellar Variant, Cirrhotic and Normal Liver. Mod Pathol 16, 14-21 (2003).
PubMed link      E-mail link

Reference Number: 75
Selden, C. et al. Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumours. J Hepatol 21, 227-34 (1994).
PubMed link      E-mail link

Reference Number: 76
Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H. & Okamoto, E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25, 619-23 (1997).
PubMed link      E-mail link

Reference Number: 403
Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther. 4, 1577-84 (2005)
PubMed link      E-mail link

Reference Number: 449
Ranganathan S, Tan X, Monga SP. beta-Catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol.  8, 435-47 (2005)
PubMed link      E-mail link

Reference Number: 450
Osada S, Kanematsu M, Imai H, Goshima S, Sugiyama Y. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg. 201, 405-11 (2005)
PubMed link      E-mail link

Reference Number: 454
Elchuri S, Oberley TD, Qi W, Eisenstein RS, Jackson Roberts L, Van Remmen H, Epstein CJ, Huang TT. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene. 24, 367-80 (2005)
PubMed link      E-mail link

Reference Number: 468
Yang H, Magilnick N, Noureddin M, Mato JM, Lu SC. Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density-dependent in HepG2 cells. J Cell Physiol. 210, 766-73 (2007)
PubMed link      E-mail link

Reference Number: 471
Tward AD, Jones KD, Yant S, Kay MA, Wang R, Bishop JM. Genomic progression in mouse models for liver tumors. Cold Spring Harb Symp Quant Biol. 70, 217-24 (2005)
PubMed link      E-mail link

Reference Number: 476
Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 116, 1582-95 (2006)
PubMed link      E-mail link

Reference Number: 477
Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W. The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy. Dig Liver Dis. 38, 490-7 (2006)
PubMed link      E-mail link

Reference Number: 611
Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A. 104, 14771-6 (2007)
PubMed link      E-mail link

Reference Number: 612
Salvi A, Arici B, Portolani N, Giulini SM, De Petro G, Barlati S. In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol. 31, 451-60 (2007)
PubMed link      E-mail link

Reference Number: 632
Takami T, Kaposi-Novak P, Uchida K, Gomez-Quiroz LE, Conner EA, Factor VM, Thorgeirsson SS. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res. 67, 9844-51 (2007)
PubMed link      E-mail link

Reference Number: 633
Towner RA, Smith N, Tesiram YA, Abbott A, Saunders D, Blindauer R, Herlea O, Silasi-Mansat R, Lupu F. In vivo detection of c-MET expression in a rat hepatocarcinogenesis model using molecularly targeted magnetic resonance imaging. Mol Imaging. 6, 18-29 (2007)
PubMed link      E-mail link

Reference Number: 645
Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, Eun JY, Kim HG, Yoon SS, Lee DS, Kim JH, Kim JR. Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target. Clin Exp Metastasis. 25, 89-96 (2008)
PubMed link      E-mail link

Reference Number: 658
Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, Nash GM, Gimbel M, Yamaguchi Y, Culliford AT 4th, D'Alessio M, Barany F, Paty PB. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett. 265, 258-69 (2008)
PubMed link      E-mail link

Reference Number: 681
Chau GY, Lui WY, Chi CW, Chau YP, Li AF, Kao HL, Wu CW. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection. Eur J Surg Oncol. 34, 333-8 (2008)
PubMed link      E-mail link

Reference Number: 717
Osada S, Kanematsu M, Imai H, Goshima S. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology. 55, 544-9 (2008)
PubMed link      E-mail link

Reference Number: 721
Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 275, 44-53 Epub 2008 Nov 8. (2009)
PubMed link      E-mail link

Reference Number: 803
Xie B, Xing R, Chen P, Gou Y, Li S, Xiao J, Dong J. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J Surg Res. 162, 231-8 (2010)
PubMed link      E-mail link

Reference Number: 900
Singhal G, Rajeswari MR. Interaction of actinomycin D with promoter element of c-met and its inhibitory effect on the expression of c-Met. J Biomol Struct Dyn. 26, 625-36 (2009)
PubMed link      E-mail link

Reference Number: 901
Patil MA, Lee SA, Macias E, Lam ET, Xu C, Jones KD, Ho C, Rodriguez-Puebla M, Chen X. Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res. 69, 253-61 (2009)
PubMed link      E-mail link

Reference Number: 903
Kaufmann R, Oettel C, Horn A, Halbhuber KJ, Eitner A, Krieg R, Katenkamp K, Henklein P, Westermann M, Böhmer FD, Ramachandran R, Saifeddine M, Hollenberg MD, Settmacher U. Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Carcinogenesis. 30, 1487-96 (2009)
PubMed link      E-mail link

Reference Number: 909
Marx-Stoelting P, Borowiak M, Knorpp T, Birchmeier C, Buchmann A, Schwarz M. Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met. Int J Cancer. 124, 1767-72 (2009)
PubMed link      E-mail link

Reference Number: 1025
Purcell R, Childs M, Maibach R, Miles C, Turner C, Zimmermann A, Sullivan M. HGF/c-Met related activation of ß-catenin in hepatoblastoma. J Exp Clin Cancer Res. 30:96 (2011)
PubMed link      E-mail link

Reference Number: 1027
Schelter F, Grandl M, Seubert B, Schaten S, Hauser S, Gerg M, Boccaccio C, Comoglio P, Krüger A. Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin Exp Metastasis. 28, 793-802 (2011)
PubMed link      E-mail link

Reference Number: 1033
Carr BI, Wang Z, Wang M, Cavallini A, D'Alessandro R, Refolo MG. c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. Cancer Biol Ther. 12, 531-8 (2011)
PubMed link      E-mail link

Reference Number: 1035
Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 9, 166 (2011)
PubMed link      E-mail link

Reference Number: 1106
Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett. 585, 2229-34 (2011)
PubMed link      E-mail link

Reference Number: 1148
Dai R, Li J, Fu J, Chen Y, Yu L, Zhao X, Qian Y, Zhang H, Chen H, Ren Y, Su B, Luo T, Zhu J, Wang H. Disturbance of Ca2 homeostasis converts pro-Met into non-canonical tyrosine kinase p190MetNC in response to endoplasmic reticulum stress in MHCC97 cells. J Biol Chem. 287, 14586-97 (2012)
PubMed link      E-mail link

Reference Number: 1227
Qu JH, Chang XJ, Lu YY, Bai WL, Chen Y, Zhou L, Zeng Z, Wang CP, An LJ, Hao LY, Xu GL, Gao XD, Lou M, Lv JY, Yang YP. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 18, 2995-3003 (2012)
PubMed link      E-mail link

Reference Number: 1258
Nguyen TH, Loux N, Dagher I, Vons C, Carey K, Briand P, Hadchouel M, Franco D, Jouanneau J, Schwall R, Weber A. Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met. Cancer Gene Ther. 10, 840-9 (2003)
PubMed link      E-mail link

Reference Number: 1273
Bozkaya G, Korhan P, Cokakli M, Erdal E, Sagol O, Karademir S, Korch C, Atabey N. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer. 11, 64 (2012)
PubMed link      E-mail link

Reference Number: 1283
Buurman R, Gürlevik E, Schäffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F, Skawran B. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology. 143, 811-20 (2012)
PubMed link      E-mail link

Reference Number: 1296
Isella C, Mellano A, Galimi F, Petti C, Capussotti L, De Simone M, Bertotti A, Medico E, Muratore A. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann Surg. 257, 1089-95 (2013)
PubMed link      E-mail link

Reference Number: 1302
Trojan J, Zeuzem S. Tivantinib in hepatocellular carcinoma. Expert Opin Investig Drugs. 22, 141-7 (2013)
PubMed link      E-mail link

Reference Number: 1335
Gao J, Feng X, Inagaki Y, Song P, Kokudo N, Hasegawa K, Sugawara Y, Tang W. Des-?-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence. Biosci Trends. 6, 153-9 (2012)
PubMed link      E-mail link

Reference Number: 1368
Ang CS, Sun MY, Huitzil-Melendez DF, Chou JF, Capanu M, Jarnagin W, Fong Y, Dematteo RP, D'Angelica M, Allen P, Chen CT, O'Reilly EM, Weiser MR, Abou-Alfa GK. c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival. Anticancer Res. 33, 3241-5 (2013)
PubMed link      E-mail link

Reference Number: 1381
Kondo S1, Ojima H, Tsuda H, Hashimoto J, Morizane C, Ikeda M, Ueno H, Tamura K, Shimada K, Kanai Y, Okusaka T. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol. 18, 207-13 (2013)
PubMed link      E-mail link

Reference Number: 1386
Ogunwobi OO1, Puszyk W, Dong HJ, Liu C. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma. PLoS One. 8, e63765 (2013)
PubMed link      E-mail link

Reference Number: 1394
Lee SJ1, Lee J, Sohn I, Mao M, Kai W, Park CK, Lim HY. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res. 33, 5179-86 (2013)
PubMed link      E-mail link

Reference Number: 1399
Hu CT1, Cheng CC, Pan SM, Wu JR, Wu WS. PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2. Cell Signal. 25, 1457-67 (2013)
PubMed link      E-mail link

Reference Number: 1425
Yang X1, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH, Qin LX. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 59, 1874-85 (2014)
PubMed link      E-mail link

Reference Number: 1457
Harun N, Costa P, Christophi C. Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met. Clin Exp Metastasis. 31, 1-14 (2014)
PubMed link      E-mail link

Reference Number: 1477
Chen CK, Yang CY, Hua KT, Ho MC, Johansson G, Jeng YM, Chen CN, Chen MW, Lee WJ, Su JL, Lai TC, Chou CC, Ho BC, Chang CF, Lee PH, Chang KJ, Hsiao M, Lin MT, Kuo ML. Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment. Hepatology. 59, 974-85 (2014)
PubMed link      E-mail link

Reference Number: 1492
Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, Zhao CH, Lin L, Brunetti AE, Fu YL, Wang J, Paradiso A, Xu JM. Expression and prognostic value of VEGFR-2, PDGFR-ß, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 32, 16 (2013)
PubMed link      E-mail link

Reference Number: 1548
Korhan P, Erdal E, Atabey N. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met. Biochem Biophys Res Commun. 450, 1304-12 (2014)
PubMed link      E-mail link

Reference Number: 1552
Kang GH, Lee BS, Lee ES, Kim SH, Lee HY, Kang DY. Prognostic significance of p53, mTOR, c-Met, IGF-1R, and HSP70 overexpression after the resection of hepatocellular carcinoma. Gut Liver. 8, 79-87 (2014)
PubMed link      E-mail link

Reference Number: 1651
Rimassa L, Santoro A, Daniele B, Germano D, Gasbarrini A, Salvagni S, Masi G, Abbadessa G, Lamar M, Goldberg T, Porta C. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers. Tumori. 101, 139-43 (2015)
PubMed link      E-mail link

Reference Number: 1662
Bogorad RL, Yin H, Zeigerer A, Nonaka H, Ruda VM, Zerial M, Anderson DG, Koteliansky V. Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice. Nat Commun. 5, 3869 (2014)
PubMed link      E-mail link

Reference Number: 1686
Mußbach F, Henklein P, Westermann M, Settmacher U, Böhmer FD, Kaufmann R. Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation. J Cancer Res Clin Oncol. 141, 813-25 (2015)
PubMed link      E-mail link

Reference Number: 1696
Korhan P, Erdal E, Kandemis E, Cokakli M, Nart D, Yilmaz F, Can A, Atabey N. Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma. PLoS One., 9(8):e105278 (2014)
PubMed link      E-mail link

Reference Number: 1788
Koh YW, Park YS, Kang HJ, Shim JH, Yu E. MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma. Tumour Biol. 36, 4993-5000 (2015)
PubMed link      E-mail link

Reference Number: 1808
Gui Y, Yeganeh M, Donates YC, Tobelaim WS, Chababi W, Mayhue M, Yoshimura A, Ramanathan S, Saucier C, Ilangumaran S Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma. Oncogene. 34, 5718-28 (2015)
PubMed link      E-mail link

Reference Number: 1825
Yao Y, Dou C, Lu Z, Zheng X, Liu Q. MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway. Cell Physiol Biochem. 35, 983-96 (2015)
PubMed link      E-mail link

Reference Number: 1827
Wu JR, Hu CT, You RI, Ma PL, Pan SM, Lee MC, Wu WS. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS One. 10, e0114495 (2015)
PubMed link      E-mail link

Reference Number: 1836
Zhao L, Wu Y, Xie XD, Chu YF, Li JQ, Zheng L. c-Met identifies a population of matrix metalloproteinase 9-producing monocytes in peritumoural stroma of hepatocellular carcinoma. J Pathol. 237, 319-29 (2015)
PubMed link      E-mail link

Reference Number: 1879
Ohta K, Hoshino H, Wang J, Ono S, Iida Y, Hata K, Huang SK, Colquhoun S, Hoon DS. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A. Oncotarget. 6, 3211-24 (2015)
PubMed link      E-mail link

Reference Number: 1900
Gui Y, Yeganeh M, Cepero-Donates Y, Ramanathan S, Saucier C, Ilangumaran S, Regulation of MET receptor signaling by SOCS1 and its implications for hepatocellular carcinoma. Curr Pharm Des. 20, 2922-33 (2014)
PubMed link      E-mail link